Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
3(50%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
6
100%

Phase Distribution

6

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
6(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(3)

Detailed Status

Completed3
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 16 (100.0%)

Trials by Status

completed350%
active_not_recruiting350%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_1

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

NCT03491683
active_not_recruitingphase_1

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

NCT04251117
active_not_recruitingphase_1

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

NCT04367675
completedphase_1

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

NCT03502785
completedphase_1

Therapeutic Vaccination in Treated HIV Disease

NCT03606213
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03491683Phase 1

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Active Not Recruiting
NCT04251117Phase 1

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Active Not Recruiting
NCT04367675Phase 1

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Active Not Recruiting
NCT03502785Phase 1

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Completed
NCT03606213Phase 1

Therapeutic Vaccination in Treated HIV Disease

Completed
NCT02960594Phase 1

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6